Nov 30 |
Chlorpheniramine for COVID-19: real-time meta analysis of 3 studies | |
Significantly lower risk is seen for recovery. 2 studies (both from the same team) show significant benefit. Meta analysis using the most serious outcome reported shows 56% [46‑64%] lower risk. Results are similar for Randomize.. | ||
Nov 26 |
et al., BMC Infectious Diseases, doi:10.1186/s12879-024-10211-8 | Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies |
90% lower PASC (p=0.001). Prospective study of 259 COVID-19 outpatients from the ACROSS-I and ACROSS-III RCTs showing significantly lower long COVID with intranasal chlorpheniramine (iCPM) compared to placebo. 72% of placebo patients experienced at least one PASC .. | ||
Dec 31 2022 |
et al., Medical Research Archives, doi:10.18103/mra.v10i3.2752 | Intranasal Chlorpheniramine Maleate for the treatment of COVID-19: Translational and Clinical Evidence |
87% lower hospitalization (p=0.08). Small RCT showing significantly improved recovery with intranasal chlorpheniramine maleate. Authors also perform an In Vitro study showing efficacy with a highly differentiated three-dimensional model of normal, human-derived tracheal/bro.. | ||
Oct 18 2022 |
et al., Research Square, doi:10.21203/rs.3.rs-2167465/v1 | Chlorpheniramine Intranasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: The ACCROS Trials |
54% faster recovery (p<0.0001). RCT and retrospective study of chlorpheniramine nasal spray for COVID-19. The retrospective study included 660 outpatients showing fewer days with general COVID-19 symptoms, cough, anosmia, and ageusia compared to standard of care alone. .. | ||
Oct 18 2022 |
et al., Research Square, doi:10.21203/rs.3.rs-2167465/v1 | Chlorpheniramine Intranasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: The ACCROS Trials |
61% improved recovery (p=0.0002) and 74% lower PASC (p=0.001). RCT and retrospective study of chlorpheniramine nasal spray for COVID-19. The RCT included 101 outpatients showing significantly faster recovery with treatment. The retrospective study results are listed separately [Valerio-Pascua]. Long .. | ||
Jan 28 2022 |
et al., Frontiers in Drug Delivery, doi:10.3389/fddev.2023.1164671 (date from preprint) | On a model-based approach to improve intranasal spray targeting for respiratory viral infections |
Computational fluid dynamics study of nasal spray administration in 2 subjects showing 100x improvement in nasopharyngeal drug delivery using a new spray placement protocol. The study also found the optimal droplet size range for nasophar.. |
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.